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Summary
BACKGROUND: The global epidemiology of methicillin-
resistant Staphylococcus aureus (MRSA) is heterogeneous.
The objective of this study was to evaluate MRSA epidemi-
ology in Switzerland over an 11-year period.
METHODS: We conducted a retrospective study with time
series analysis on S. aureus including MRSA and non-mul-
tidrug resistant MRSA (NmMRSA). We used NmMRSA as
a marker for community-acquired MRSA. NmMRSA was
defined as MRSA susceptible to at least three of the fol-
lowing agents: ciprofloxacin, clindamycin, tetracycline and
trimethoprim-sulfamethoxazole.
RESULTS: A total of 14 648 MRSA and 115 917
methicillin-susceptible S. aureus (MSSA) isolates were in-
cluded. Despite an overall decrease of the proportion of
MRSA among S. aureus clinical isolates (from 14% in
2004 to 8% in 2014), an increasing trend in NmMRSA
was observed. Variations in geographical distribution were
noted, with a decrease in the proportion of MRSA in the
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Italian- and French-speaking regions (from 20–26% in
2004 to 12% in 2014) and low prevalence (3–5%) in the
German-speaking region. We noticed an increase in the
proportion of MRSA in outpatients (+0.03% per quarter per
year) and in the younger population (+0.05% per quarter
per year) compared with a decreasing trend in inpatients
and the elderly.
CONCLUSION: The proportion of MRSA among S. aure-
us isolates in Switzerland decreased overall from 2004 to
2014. Worrisome increases of NmMRSA were found in
younger persons and outpatients.
Key words: MSSA; MRSA; non-multidrug resistant MRSA;
time series analysis; trend; bacteraemia
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) com-
bines virulence and resistance with remarkable adaptive
qualities to the human host and is associated with either
carriage or a broad spectrum of infectious conditions caus-
ing significant clinical and health-economic adverse out-
comes [1]. Initially, MRSA infections were largely a
healthcare-associated problem, but over time they have
emerged increasingly in the community as well. Currently,
global MRSA epidemiology remains heterogeneous, with
several Asian countries [2] reporting some of the highest
MRSA rates worldwide [3].
Regarding Europe, recent data from the European antimi-
crobial resistance interactive database (EARS-Net), which
covers a wide network of national surveillance systems
in Europe, show that, after a general rise in prevalence,
MRSA proportions among S. aureus isolates seem to be
decreasing in Europe since the beginning of this decade,
as observed also in North America [3]. It is, however,
a heterogeneous picture as Sweden, Estonia, Austria and
Romania still show rising trends in MRSA prevalence
(European Centre for Disease Prevention and Control,
ECDC 2013). There is a paucity of comparable epidemi-
ological data from Switzerland, which offers a unique per-
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spective for epidemiological analysis of temporal MRSA
trends because of its central position in Europe and its
three main linguistic regions (German, French and Italian),
which have strong cultural and economic ties to neigh-
bouring countries. The last national survey on MRSA epi-
demiology in Switzerland was conducted in 1997 [4] and
showed low rates of MRSA in most hospitals.
The objective of this study was to evaluate the epidemi-
ology and temporal trends of MRSA and methicillin-sus-
ceptible S. aureus (MSSA) infections in Switzerland from
2004 to 2014. This analysis of Swiss antimicrobial resist-
ance rates was intended to complement the European pic-
ture and demonstrate that important differences may be ob-
served even in different regions within the same country.
Methods
Data
This observational laboratory-based study was conducted
with use of the database from the Swiss antimicrobial res-
istance surveillance network (ANRESIS, www.anresis.ch)
available since 2004. This database provides antibiotic res-
istance data for all routinely collected microbiological
samples from 20 clinical microbiology laboratories, dis-
tributed all over Switzerland and representing at least 70%
of annual hospitalisation days and 30% of all Swiss general
practitioners [5]. For this study we included data from
the 12 laboratories that continuously contributed data from
2004 to 2014. While the number of ambulatory samples
increased over time in this subset, for in-patient samples
(which were used for calculation of incidence rates) we
restricted the analysis to the 36 hospitals linked to these
laboratories, which sent continuous data during the whole
study period. These hospitals represent at least 40% of an-
nual hospitalisation days in Switzerland. This surveillance
data includes data from primary and tertiary care hospitals,
outpatient clinics and ambulatory practices.
Antimicrobial susceptibility was tested at local laboratories
according to Clinical and Laboratory Standards Institute
(CLSI, www.clsi.org) or European Committee on Antimi-
crobial Susceptibility Testing (EUCAST, www.eucast.org)
guidelines. Most of the participating laboratories switched
from CLSI to EUCAST breakpoints between 2011 and
2013. All participating laboratories are participating in at
least one external quality programme out of the National
External Quality Assessment Service (NEQAS,
www.ukneqasmicro.org.uk) or the Swiss quality control
programme from the Institute for Medical Microbiology,
University of Zürich (http://www.imm.uzh.ch/services/
qc.html). Results from MRSA screening swabs and from
duplicates, defined as isolates with identical antimicrobial
resistance profiles isolated from the same patient within
1 year, were excluded from the analyses. For calculation
of incidence rates for bloodstream infections, we used data
from inpatients only, and the duplicate algorithm was re-
stricted to blood cultures. Methicillin resistance was
defined as nonsusceptibility to at least one out of oxacillin,
flucloxacillin, methicillin or cefoxitin. Isolates not tested
against any of these antibiotics were excluded from analys-
is (n = 795).
The epidemiological data allowed stratification of isolates
by sex, age group (<16, 16–65, >65 years), linguistic re-
gion (German, French or Italian), in- versus outpatients,
and site of isolation (invasive [isolation from usually sterile
body sites] versus noninvasive). Bloodstream infections
were analysed separately, too.
We used the term non-multidrug resistant MRSA
(NmMRSA) as a potential marker for community-associ-
ated strains of MRSA (CA-MRSA), because of similarit-
ies in epidemiology [6] and phenotypic antimicrobial sus-
ceptibility [7]. NmMRSA was defined as MRSA suscept-
ible to at least three of the following agents – ciprofloxa-
cin, clindamycin, tetracycline or trimethoprim-sulfameth-
oxazole (TMP/SMX) – while remaining resistant to all
beta-lactam antibiotics.
Statistical analysis
We calculated the annual incidence of MRSA, NmMRSA
and MSSA bacteraemia and invasive isolates per 100 000
hospital admissions. Assuming that patients with bacter-
aemia and other invasive isolates are usually hospitalised,
we restricted our dataset to inpatients only for this analysis.
Univariate logistic regression was performed to determine
the association between age, sex, in-/outpatient, region, in-
vasive/noninvasive sample origin, as explanatory variables,
and MRSA versus MSSA, and NmMRSA versus mMRSA
(multidrug-resistant MRSA), as dependent variables. The
explanatory variables were selected on the basis of data
availability. We considered at least 10 events for each ex-
planatory variable analysed. Using the explanatory vari-
ables from the univariate analysis with a value of p <0.2,
we built two multivariate regression models (NmMRSA vs
mMRSA; and MRSA vs MSSA). However, there are some
potential limitations with this method of selecting explanat-
ory variables because it is known that more complex mod-
els tend to give overoptimistic predictions, especially when
extensive variable selection has been performed [8].
We conducted several time series analyses of MRSA trends
stratified by age group, in- versus outpatient population
and linguistic region. The same analysis was performed
with the proportion of resistance to selected drugs (such
as ciprofloxacin, fusidic acid, clindamycin and erythromy-
cin) among MRSA strains. To perform the time series ana-
lyses, we used an autoregressive integrated moving average
(ARIMA) model, which is considered a suitable method to
monitor and predict the trend of bacterial resistance preval-
ence when using surveillance data [9]. With the Box-Jen-
kins method, checks were made to determine whether the
time series was stationary by use of the augmented Dickey-
Fuller test for unit root [10]. The models were identified
by determining the ARIMA model orders (p, q, d) through
consideration of the autocorrelation and partial autocor-
relation profiles. Finally, we evaluated the adequacy of
the models using a Durbin Watson test for the statistic-
al significance of the parameters [11]. In general, the ana-
lyses sought to identify the most parsimonious model with
the fewest parameters. The time series analyses were per-
formed in Eviews version 18, all other analyses were car-
ried out in STATA 13.
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Ethics
Since the database contains routinely collected anonymised
non-genetic surveillance data, ethical consent was not re-
quired according to the Swiss law for research on human
beings (Art. 33 al. 2 LRH).
Results
The 12 laboratories included in the analysis reported
130 565 samples positive for S. aureus, including 115 917
MSSA and 14 648 MRSA (with 3179 [22%] NmMRSA)
isolates, over the period from January 2004 to December
2014. Demographic and clinical characteristics of patients
in the different groups are shown in table 1.
Times series analysis
General data
The overall proportion of MRSA among S. aureus isolates
decreased from 14% in 2004 to 8% in 2014, with a decreas-
ing trend (–0.08% per quarter, p <0.01). Conversely, the re-
lative proportion of NmMRSA among all MRSA increased
Figure 1
Proportion of methicillin-resistant S. aureus (MRSA) among
S. aureus isolates by region.
Red = German-speaking; green = French-speaking; yellow =
Italian-speaking
from 8 % in 2004 to 43% in 2014 (+0.92% per quarter, p =
0.04).
Linguistic regions
Differences were found across the linguistic regions. In
the French- and Italian-speaking regions, MRSA propor-
tions were decreasing over time (–0.28% and –0.15% per
quarter, respectively, p <0.01; fig. 1), while in the German-
speaking region MRSA trends were on a slightly upward
trajectory (+0.03% per quarter, p <0.01; fig. 1). Never-
theless, MRSA rates remained significantly higher in the
French- and Italian-speaking regions throughout the whole
time period. Conversely, NmMRSA was increasing in all
regions (Italian region, +0.42% per quarter, p <0.01;
French region, +0.8% per quarter, p <0.01; German-speak-
ing region, +0.92% per quarter, p <0.01).
Inpatient versus outpatient population
MRSA rates were significantly lower in outpatients, but in-
creased from 2008 to 2014, (0.03% per quarter, p <0.01),
while MRSA prevalence decreased in inpatients during the
same time period (–0.18% per quarter, p <0.01).
For NmMRSA strains, however, an increasing trend was
noticed for both in- and outpatients (+1.07% and +0.61%
per quarter, respectively, p <0.01).
Age and sex
MRSA was increasing in the younger population (+0.05%
per quarter, p <0.01), but decreasing in the adult and elderly
groups (–0.30% and – 0.02% per quarter, respectively, p
<0.01). However, the proportion of NmMRSA strains in all
three age groups increased over time (data not shown).
Males were more likely to be infected by MRSA. This find-
ing was stable over the 11 years of surveillance (table 1).
Table 1: Characteristics of patients with MRSA, MSSA, or NmMRSA infections (2004–2014).
MSSA in % of S. aureus
(n = 115 917)
MRSA in % of S. aureus
(n = 14 648)
NmMRSA in % of MRSA
(n = 3179)
Linguistic region
German 69 054 (95.3%) 3389 (4.7%) 1349 (39.8%)
French 36 764 (79.9%) 9279 (20.1%) 1099 (11.8%)
Italian 10 008 (83.5%) 1980 (16.5%) 731 (36.9%)
Sex
Male 62 019 (88%) 8649 (12%) 1680 (19.4%)
Female 53 773 (90%) 5982 (10%) 1496 (25%)
In- versus outpatient
Inpatient 55 830 (84.1%) 10 604 (15.9%) 1858 (17.5%)
Outpatient 59 781 (93.9%) 3897 (6.1%) 1265 (32.5%)
ICU versus other departments
ICU 7588 (90.7%) 776 (9.3%) 139 (17.9%)
Non-ICU 48 241 (83.1%) 9828 (16.9%) 1719 (17.5%)
Age group
<16 years 22 372 (95.9%) 971 (4.1%) 397 (40.9%)
16–65 years 60 583 (92.4%) 4984 (7.6%) 1498 (30%)
>65 years 32 962 (79.1%) 8693 (20.9%) 1284 (14.7%)
Invasive versus noninvasive
Invasive 19 384 (91.6%) 1775 (8.4%) 530 (29.9%)
Noninvasive 96 533 (88.3%) 12 873 (11.7%) 2649 (20.6%)
ICU = intensive care unit; MRSA = methicillin-resistant S. aureus; MSSA = methicillin-susceptible S. aureus; NmMRSA = non-multidrug resistant MRSA
In the first column, for each variable (linguistic regions, sex…), the distribution of MSSA in every category is shown (per row). There are some missing data for each
variable. Within each row the numbers in the first two columns add up to 100%. The percentages in the third column are a proportion of NmMRSA of all MRSA in each
subcategory.
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Antibiotic resistance
Over the study period, resistance to ciprofloxacin, clinda-
mycin, gentamicin and erythromycin in MRSA strains de-
creased (fig. 2). In contrast, resistance to tetracycline,
TMP/SMX, fusidic acid and rifampicin remained constant
and low over the study period (data not shown). Antibiotic
resistance to clindamycin and ciprofloxacin was highest in
the French- and Italian-speaking regions. In comparison, in
the German speaking-region, resistance to gentamicin and
erythromycin was more prevalent (see appendix).
Sample type and incidence rates
The proportion of MRSA among S. aureus decreased for
invasive isolates (–0.10% per quarter, p <0.01) and nonin-
vasive isolates (–0.09% per quarter, p <0.01), whereas the
proportion for NmMRSA among MRSA increased for in-
vasive (+1.04% per quarter, p <0.01) and noninvasive isol-
ates (+0.83% per quarter, p = 0.02).
Considering invasive isolates only, we found decreasing
MRSA proportions in blood cultures from 14% in 2004
to 5% in 2014 for S. aureus and for other invasive infec-
tions from 16% to 13%. After extrapolation to the whole
Swiss population, the incidence of mMRSA bacteraemia
decreased from 21 to 7 per 100 000 admissions, whereas
the incidence of other invasive mMRSA infections de-
creased only from 11 to 10 per 100 000 admissions (fig.
3a). Although we observed a true increase in NmMRSA
in invasive infections (from 4 to 14 per 100 000 admis-
sions), incidence of NmMRSA in bloodstream infections
remained stable over time (from 4 to 3 per 100 000 admis-
sions, fig. 3b). While the incidence of MSSA bacteraemia
decreased until 2013, this was not the case for other invas-
ive MSSA infections.
Risk factors of MRSA and NmMRSA
The results of the univariate regression analyses are repor-
ted in table 2A. Location in the French and Italian linguist-
ic regions, inpatient status and elderly age were signific-
ant risk factors for MRSA, but not for NmMRSA. Invasive
isolates, younger age and outpatient status were identified
as risk factors for NmMRSA but not for MRSA in gener-
al. Outpatient status was protective against MRSA. Simil-
ar results were found in the multivariate regression models
(table 2B) using the dependent variables of MRSA versus
MSSA and NmMRSA versus mMRSA. The first model
confirmed the same risk factors for MRSA (French and
Figure 2
Time series analysis of antibiotic resistance among methicillin-
resistant S. aureus (MRSA) isolates. Trends per quarter are given
in parentheses.
Italian linguistic regions and elderly) and the same protect-
ive factors (younger age group, invasive isolates and out-
patient group); conversely, in the second model young age,
outpatient status, invasive isolates and the Italian-speaking
region were risk factors for NmMRSA isolation; whereas
location in the French-speaking region and being elderly
were protective against NmMRSA.
Discussion
This large-scale national resistance surveillance study de-
scribed the epidemiology of MRSA in Switzerland over 11
years, revealing an overall downward trend across the vari-
ous patient groups. In particular, the French- and Italian-
speaking regions moved from endemic MRSA prevalence
to moderate MRSA rates. In contrast to the general MRSA
trend, we found a general increase in NmMRSA (as marker
of CA-MRSA) during these 11 years, in particular for
younger age groups, outpatients and invasive isolates.
Considering the regional distribution of MRSA rates and
trends, we noted relevant regional differences with both a
north-south and an east-west gradient. The geographical,
cultural and economic ties of the Italian- and French-speak-
ing regions of Switzerland to Italy and France (where the
prevalences of MRSA as reported by ECDC were 36% and
17%, respectively, ECDC 2013) may in part explain the
higher MRSA prevalence in these regions compared with
the German-speaking region that borders with countries
with lower MRSA rates (Germany, 12.7%; Austria, 9.2%
in 2013, ECDC data).
Several lines of argumentation have been tried to explain
the different geographic distribution of antibiotic-resistant
microorganism between countries and continents. Import-
ant determinants are country-specific factors related to an-
tibiotic resistance, like the organisation of the healthcare
system with reimbursement structures and incentives, dia-
gnostic practices, laboratory recognition, antibiotic use,
and physician and patient attitudes and expectations [12,
13]. In fact, differences in the approaches to control MRSA
dissemination amongst countries neighbouring Switzerland
help to explain their differences in MRSA endemicity. For
example Italy, which delayed the implementation of strict
control measures, now is endemic for MRSA. On the other
hand, France, which implemented control measures faster,
was able to stabilise or even decrease MRSA prevalence
in confined geographic areas. Even more striking was the
case of central European countries like Germany that man-
aged to maintain MRSA at a low level using multiple ap-
Figure 3
Incidence of methicillin-susceptible S. aureus (MSSA), non-
multidrug resistant methicillin-resistant S. aureus (NmMRSA) and
multidrug resistant methicillin-resistant S. aureus (mMRSA) per
100 000 hospital admissions (a) in invasive isolates (excluding
bacteraemic isolates) and (b) in bacteraemia.
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proaches such as restricting antibiotic usage, and enforce-
ment of screening and contact precautions [3].
Switzerland had adopted more local than national ap-
proaches to control MRSA dissemination. Following the
first national MRSA surveillance study in 1997 [4], limited
surveillance, elaboration of guidelines and interventions to
control MRSA dissemination were conducted at a nation-
al level [14]. This has led to marked heterogeneity between
regions.
Our finding of a general upward trend of NmMRSA in
all of Switzerland is in line with the rapid global dis-
semination of CA-MRSA with different clonal outbreaks
in Europe, the USA and the rest of the world, especially
among younger age groups and outpatients [15]. The first
imported case of CA-MRSA in Switzerland was reported
in 2002 [16], followed by other reports, such as the out-
break of a Panton–Valentine leukocidin (PVL)-positive
ST5-IV strain in a neonatal intensive care unit in Geneva
[17].
Antibiotic resistance rates in MRSA strains against non-
beta-lactam antibiotics such as ciprofloxacin, clindamycin,
gentamicin and erythromycin decreased, while resistance
rates to other compounds (tetracycline, TMP/SMX, fusidic
acid and rifampicin) remained stable. These findings could
be explained by a decrease in multiresistant hospital-ac-
quired (HA-MRSA) isolates in regions with previously en-
demic MRSA incidence. This decrease is potentially linked
to an interplay between a loss of biological fitness in en-
demic HA-MRSA clones [18] and improved infection con-
Table 2A: Risk factors for MRSA (vs MSSA) and NmMRSA (vs mMRSA) by univariable logistic regression analysis.
MRSA vs MSSA NmMRSA vs mMRSA
Stratification Odds ratio 95% CI Odds ratio 95% CI
Linguistic region
German 1* 1*
French 5.14 4.90–5.30 0.20 0.10–0.20
Italian 4.03 3.70–4.20 0.80 0.70–0.90
In- versus outpatient
Inpatient 1* 1*
Outpatient 0.34 0.33–0.35 2.26 2.08–2.45
ICU versus other departments
Non-ICU 1* 1*
ICU 0.50 0.46–0.54 1.02 0.85–1.24
Age group
<16 years 0.52 0.49–0.56 1.60 1.39–1.85
16–65 years 1* 1*
>65 years 3.20 3.08–3.33 0.40 0.37–0.44
Invasive versus noninvasive
Noninvasive 1* 1*
Invasive 0.68 0.65–0.72 1.64 1.47–1.83
CI = confidence interval; ICU = intensive care unit; mMRSA = multidrug-resistant MRSA; MRSA = methicillin-resistant S. aureus; MSSA = methicillin-susceptible S. aureus;
NmMRSA = non-multidrug resistant MRSA
* Reference category, adjusted for all other variables listed in the table
Table 2B: Results from multivariate logistic regression comparing the risk factors for MRSA versus MSSA and NmMRSA versus mMRSA.
MRSA vs MSSA NmMRSA vs mMRSA
Stratification Odds ratio 95% CI Odds ratio 95% CI
Linguistic regions
German 1* 1*
French 4.41 4.23–4.61 0.28 0.26–0.32
Italian 3.19 3.00–3.40 1.30 1.14–1.46
In- versus outpatient
Inpatient 1* 1*
Outpatient 0.38 0.37–0.40 1.57 1.43–1.72
ICU versus other departments
ICU Omitted because of collinearity† 1.02 0.85–1.24
Age group
<16 years 0.71 0.66–0.76 1.60 1.39–1.85
16–65 years 1* 1*
>65 years 2.49 2.40–2.59 0.40 0.37–0.44
Invasive versus noninvasive
Noninvasive 1* 1*
Invasive 0.61 0.57–0.64 1.25 1.40–2.40
CI = confidence interval; ICU = intensive care unit; mMRSA = multidrug-resistant MRSA; MRSA = methicillin-resistant S. aureus; MSSA = methicillin-susceptible S. aureus;
NmMRSA = non-multidrug resistant MRSA
* Reference category, adjusted for all other variables listed in the table
† Collinearity with variable "inpatient"
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trol measures with increased hand hygiene compliance and
other infection control measures [19–21].
A further explanation could be the replacement of HA-
MRSA clones with CA-MRSA strains [22], which are
characterised by lower rates of resistance and greater fit-
ness by virtue of their smaller SCCmec cassettes. In the ab-
sence of molecular characterisation in this study, we used
antibiotic resistance phenotypes as correlates, which have
been used to distinguish between HA-MRSA and CA-
MRSA strains in the past [23]. Thus, dissemination of
CA-MRSA strains is likely to be the main reason for the
observed increase in the sensitivity of MRSA to some an-
tibiotics, such as gentamicin, as described by De Angelis
et al., with the replacement of older strains containing the
SCCmec I cassette (a marker of HA-MRSA strains) by
newer strains with the SCCmec IV cassette (a marker for
CA-MRSA) [24].
The decrease in resistance of MRSA strains to ciprofloxa-
cin can also be partially attributed to the reduction of cipro-
floxacin use in Switzerland [25]. In fact there is ample
evidence [19, 26] that there is a strong correlation between
the use of fluoroquinolones and predisposition to colonisa-
tion or infection with MRSA. Indeed, Charbonneau et al.
[27] demonstrated how a restriction of fluroroquinolones
use led to a decreased rate of MRSA.
This study has a number of limitations. Firstly, not all hos-
pitals and medical practitioners were included in the ana-
lysis, and the regions were not equally represented (in par-
ticular the German-speaking region was underrepresented).
Secondly, we did not have molecular epidemiology ana-
lyses at our disposal requiring us to approximate the phen-
otypic definition of NmMRSA to represent CA-MRSA.
However, this approach has been taken repeatedly in the
past, as several investigators have used NmMRSA as a sur-
rogate of CA-MRSA [6, 7]. Thirdly, similarly to most na-
tional surveillance databases, we lacked detailed clinical
data to enable distinction between MRSA carriage and in-
fection. Furthermore the choice of antimicrobials in the an-
tibiograms in respiratory and wound samples could vary
from one centre to another. Considering these limiting
factors, we recommend that our findings be interpreted
with caution.
In conclusion, our study represents the most recent and
comprehensive national S. aureus surveillance study in
Switzerland and is intended to fill a gap in the European
MRSA map. It confirms the low MRSA prevalence in
Switzerland compared to the rest of Europe. At the same
time our study illustrates the regional differences and
trends which may be affected by surrounding countries and
thus cultural influences. Compared to many other nation-
al S. aureus databases, ANRESIS contains data on both in-
vasive and noninvasive infections and MSSA, MRSA and
NmMRSA. This comprehensive dataset mirrors the suc-
cessful efforts to reduce MRSA incidences observed in
many countries worldwide with a simultaneous increase in
NmMRSA likely reflecting the concomitant emergence of
CA-MRSA.
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Appendix: Supplementary tables
Table S1: Time series analysis.
All MRSA NmMRSA
R2 SEa t-statistic
(p-value)
R2 SEa t-statistic (p-value)
C:12.98 0.48 26.90 (<0.01) C:2.33 1.13 2.06 (0.04)
T:–0.08% 0.01 –4.81 (<0.01) T:0.92% 0.04 22.75 (<0.01)
AR(3) 0.18 2.53 (<0.01) AR(1) 0.07 10.71 (<0.01)
Switzerland 0.52
MA(3) 0.65 –13.66 (<0.01)
0.88
MA(1) 0.09 –10.63 (<0.01)
Linguistic region
C:3.87 0.34 11.35 (<0.01) C:18.61 6.5 2.86 (<0.01)
T:0.03% 0.01 2.68 (<0.01) T:0.92% 0.24 3.72 (<0.01)
German 0.39
AR(1) 0.14 2.83 (<0.01)
0.68
AR(1) 0.13 3.89 (<0.01)
C:19.76 0.78 25.21 (<0.01) C:29.78 1.17 25.40 (<0.01)
T:–0.15% 0.03 –4.93 (<0.01) T:0.42% 0.08 4.66 (<0.01)
AR(1) 0.10 –7.39 (<0.01) AR(3) 0.63 –11.91 (<0.01)
Italian 0.46
MA(1) 0.05 17.29 (<0.01)
0.37
MA(1) 0.68 15.88 (<0.01)
C:26.19 1.06 24.49 (<0.01) 4.61 1.44 –3.19 (<0.01
T:–0.28% 0.04 –6.81 (<0.01) T:0.8% 0.05 15.15 (<0.01)
AR(0) – – AR(3) 0.17 2.27 (0.02)
French 0.66
MA(4) 0.14 2.62 (<0.01)
0.86
MA(3) 0.04 –19.49 (<0.01)
In- versus outpatient
C:19.69 0.83 23.55 (<0.01) C:0.47 0.16 2.90 (<0.01)
T:–0.18% 0.03 –5.5 (<0.01) T:1.07% 0.01 2.81 (<0.01)
Inpatient 0.59
MA(1) 0.14 2.79 (<0.01)
0.62b
MA(1) 0.20 –6.29 (<0.01)
C:5.44 0.15 35.3 (<0.01) C:18.42 1.87 9.82 (<0.01)
T:0.03% 0.01 4.78 (<0.01) T:0.61% 0.07 8.76 (<0.01)
AR(0) – – AR(2) 0.04 19.61 (<0.01)
Outpatient 0.28
MA(2) 0.14 –2.75 (<0.01)
0.70
MA(2) 0.08 –8.50 (<0.01)
Age-group
C:3.21 0.31 10.27 (<0.01) C:12.63 5.16 2.44 (<0.01)
T:0.05 0.01 4.78 (<0.01) T:1.14% 0.20 5.56 (<0.01)
AR(2) 0.11 4.59 (<0.01) AR(0) – –
<16 years 0.59
MA(2) 0.02 –42.83 (<0.01)
0.61
MA(1) 0.14 2.60 (<0.01)
C:8.01 0.19 40.45 (<0.01) C:6.01 2.53 2.37 (0.02)
T:–0.02% 0.01 –2.98 (<0.01) T:1.17% 0.09 11.76 (<0.01)
16–65 years 0.21
MA(2) 0.14 –3.1 (<0.01)
0.84
MA(4) 0.15 2.00 (0.05)
C:27.42 0.33 82.85 (<0.01) C:3.45 1.01 3.41 (<0.01)
T:–0.3% 0.01 –21.78 (<0.01) T:0.53% 0.05 9.72 (<0.01)
AR(0) – – AR(1) 0.11 6.3 (<0.01)
>65 years 0.77
MA(3) 0.06 –13.66 (<0.01)
0.76b
MA(1) 0.15 1.43 (0.15)
Invasive versus noninvasive
C:13.94 0.55 25.09 (<0.01) C:4.17 1.81 2.29 (0.02)
T:–0.09% 0.02 –4.48 (<0.01) T:0.83% 0.07 11.50 (<0.01)
Noninvasive 0.45
MA(1) 0.15 2.22 (<0.01)
0.85
MA(1) 0.14 2.23 (0.03)
C:10.77 0.45 23.77 (<0.01) C:2.56 0.11 21.44 (<0.01)
T:–0.10% 0.14 –7.1 (<0.01) T:1.04% 0.15 6.96 (<0.01)
AR(2) 0.06 –14.20 (<0.01) AR(0) – –
Invasive 0.50
MA(2) 0.05 18.78 (<0.01)
0.70c
MA(2) 0.14 2.70 (<0.01)
AR = autoregressive term; C = constant; MA = moving average term; T = trend per quarter; a standard error; b first difference; c logarithm
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Table S2: Percentage of antibiotic resistance among MRSA strains.
Linguistic region Ciprofloxacin Clindamycin Erythromycin Fusidic acid Gentamicin Rifampicin TMP/SMX
German
2004 67 46 61 9 14 4 7
2005 64 38 61 16 25 7 8
2006 62 32 53 13 21 4 3
2007 55 27 47 18 29 4 4
2008 60 42 54 7 14 4 6
2009 51 30 41 10 19 3 7
2010 52 29 46 10 12 4 5
2011 48 24 46 9 20 1 7
2012 35 22 43 9 21 1 7
2013 44 24 50 7 20 4 12
2014 49 25 51 7 19 4 7
French
2004 97 89 91 5 56 3 1
2005 95 85 88 7 75 3 3
2006 95 86 90 4 41 4 1
2007 95 87 90 5 42 3 2
2008 93 84 86 4 30 4 2
2009 85 77 80 6 44 3 2
2010 83 72 77 7 43 3 2
2011 86 76 81 5 37 3 3
2012 78 65 70 8 55 2 2
2013 76 61 66 7 47 5 2
2014 70 51 56 6 26 5 4
Italian
2004 97 61 73 19 12 3 0
2005 93 59 68 16 27 0 1
2006 98 67 70 5 10 2 1
2007 93 60 62 3 6 0 2
2008 97 54 58 1 2 0 3
2009 92 60 63 4 6 2 4
2010 93 40 46 6 2 0 1
2011 88 46 48 7 1 4 2
2012 84 48 49 20 2 6 3
2013 88 52 54 0 0 1 5
2014 83 44 51 12 1 0 7
TMP/SMX = trimethoprim-sulfamethoxazole
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Figures (large format)
Figure 1
Proportion of methicillin-resistant S. aureus (MRSA) among S. aureus isolates by region.
Red = German-speaking; green = French-speaking; yellow = Italian-speaking
Figure 2
Time series analysis of antibiotic resistance among methicillin-resistant S. aureus (MRSA) isolates. Trends per quarter are given in parentheses.
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Figure 3
Incidence of methicillin-susceptible S. aureus (MSSA), non-multidrug resistant methicillin-resistant S. aureus (NmMRSA) and multidrug resistant
methicillin-resistant S. aureus (mMRSA) per 100 000 hospital admissions (a) in invasive isolates (excluding bacteraemic isolates) and (b) in
bacteraemia.
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